As of June 25, 2020, the Options Lab received federal funding for a COVID-19 clinical trial which aims to investigate if a 14 day course of oral Kaletra (lopinavir/ritonavir), which is currently used as one strategy for HIV post-exposure prophylaxis (PEP), is effective as COVID-19 PEP.

More information can be found here.